S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
NYSE:NUVB

Nuvation Bio (NUVB) Stock Price, News & Analysis

$3.64
-0.33 (-8.31%)
(As of 03/28/2024 ET)
Today's Range
$3.57
$4.16
50-Day Range
$1.46
$3.96
52-Week Range
$0.95
$4.16
Volume
5.51 million shs
Average Volume
1.99 million shs
Market Capitalization
$793.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Nuvation Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
92.3% Upside
$7.00 Price Target
Short Interest
Healthy
1.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Nuvation Bio in the last 14 days
Based on 27 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.36) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.78 out of 5 stars

Medical Sector

463rd out of 939 stocks

Pharmaceutical Preparations Industry

224th out of 444 stocks

NUVB stock logo

About Nuvation Bio Stock (NYSE:NUVB)

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

NUVB Stock Price History

NUVB Stock News Headlines

4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Nuvation Bio (NYSE:NUVB) Reaches New 1-Year High at $2.65
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Nuvation Bio (NYSE:NUVB) Upgraded by BTIG Research to "Buy"
Nuvation Bio (NYSE:NUVB) Trading 5.1% Higher
NUVB Apr 2024 2.000 put
NUVB Apr 2024 0.500 call
See More Headlines
Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+92.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-75,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.76 per share

Miscellaneous

Free Float
139,353,000
Market Cap
$793.70 million
Optionable
Optionable
Beta
1.19
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. David T. Hung M.D.Dr. David T. Hung M.D. (Age 66)
    Founder, President, CEO & Director
    Comp: $944.51k
  • Dr. David C. Hanley Ph.D. (Age 54)
    Chief Technical Operations Officer
    Comp: $586.04k
  • Mr. Moses Makunje (Age 45)
    Principal Accounting Officer & Principal Financial Officer
  • Dr. Gary Hattersley Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $687.88k
  • Ms. Stacy Markel (Age 59)
    Chief People Officer
  • Ms. Kerry A. Wentworth (Age 51)
    Chief Regulatory Officer
  • Dr. David Liu M.D. (Age 54)
    Ph.D., Chief Medical Officer

NUVB Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvation Bio stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVB shares.
View NUVB analyst ratings
or view top-rated stocks.

What is Nuvation Bio's stock price target for 2024?

4 brokers have issued 1 year price objectives for Nuvation Bio's stock. Their NUVB share price targets range from $5.00 to $10.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price.
View analysts price targets for NUVB
or view top-rated stocks among Wall Street analysts.

How have NUVB shares performed in 2024?

Nuvation Bio's stock was trading at $1.51 at the start of the year. Since then, NUVB stock has increased by 141.1% and is now trading at $3.64.
View the best growth stocks for 2024 here
.

When is Nuvation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NUVB earnings forecast
.

How were Nuvation Bio's earnings last quarter?

Nuvation Bio Inc. (NYSE:NUVB) posted its quarterly earnings results on Thursday, February, 29th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04.

What ETF holds Nuvation Bio's stock?

Range Cancer Therapeutics ETF holds 70,984 shares of NUVB stock, representing 1.25% of its portfolio.

Who are Nuvation Bio's major shareholders?

Nuvation Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.34%), Vanguard Group Inc. (3.35%), Northern Trust Corp (0.56%), Charles Schwab Investment Management Inc. (0.51%), Octagon Capital Advisors LP (0.46%) and Goldman Sachs Group Inc. (0.36%). Insiders that own company stock include Fund V LP Omega, Kathryn E Falberg and Oleg Nodelman.
View institutional ownership trends
.

How do I buy shares of Nuvation Bio?

Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NUVB) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners